Trump has threatened 200% tariffs on drug imports but offered pharma firms up to 18 months to shift production to the US. While companies like Eli Lilly and J&J are investing locally, concerns over costs and supply risks remain. Analysts see near-term relief due to delays, but PhRMA called the move 'counterproductive'. Final tariff details are due by the end of the month.